TIANMU drug industry met prodigal big shareholder private selling shares less earn 17 million

If the original was not inexplicably sold by half of the venture capital company shares, Tianmu Pharmaceutical 3 years ago in the venture investment business of 22 million yuan, now at least can turn the hand to earn 40 million yuan profit.　　But for now, the Tianmu pharmaceutical industry is estimated to have only half the crop.　　Venture to bear fruit July 26, will be landing on the gem of the two-forest shares (300100) and the National Teng Electronics (300101) began online purchase.　　In accordance with the final price of the two companies confirmed July 22, the dual-forest shares of 20.91 yuan/shares, after the listing, its market value of nearly 2 billion yuan, while the IPO price is 32 yuan/share, after listing its market value will also be as high as 2.2 billion yuan.　　At the same time, the company has been approved by the SFC to wait for the listing of the Thai-won wind energy, in accordance with its 2009 per share of the earnings of 0.93 yuan, the total market value will likely reach 5.4 billion yuan. Of the 3 companies that are about to land on the gem, they all have a common shareholder-Shanghai lead-Link Venture capital Co., Ltd. (hereinafter referred to as a VC).　　Among them, the joint venture to hold a dual-forest shares of 7.6 million shares, accounting for 8.13% of the issued capital, the holder of the electronic 2.5 million shares, accounting for the issuance of 3.6% of the share capital, the possession of the Thai-sheng wind energy 2.92 million shares, accounting for the issuance of capital 3.24%. If the market value of the 3 companies ' shares is added, the earnings will be close to 370 million yuan after the 3 gem companies are listed.　　That is close to 500% per cent, compared with the 63 million-dollar investment in 3 companies previously received by Huiyuan.　　Stock rights by the management of private sales according to the information of the press, the collar was founded in September 2007, is the Xuhui district of Shanghai Sasac's state-owned Assets Investment Management Co., Ltd., combined with the Shanghai Venture Capital Co., Ltd. and Jiang, Zhejiang provinces 11 private Enterprises jointly funded, registered capital of 220 million yuan. and Tianmu pharmaceutical industry is one of these 11 private enterprises.　　September 2007, according to the company's board of directors decided that the days of the pharmaceutical industry to invest 22 million yuan participation in the joint venture, accounting for the company's shares than 10%, ranked third largest shareholder. However, just a year later, July 8, 2008, the company's management in the absence of a board of directors, also did not publish any announcement of the situation, without authorization and Shanghai Songshan Real Estate Co., Ltd. (Songshan Real Estate) signed a two share transfer agreement, will hold a 4.5% equity transfer to Songshan real estate, The transfer price is 11.385 million yuan.　　According to the company after the explanation is, this 11.385 million yuan, there are 9.9 million yuan is the 4.5% equity of the principal, and the extra 1.485 million yuan, is the company in the equity transfer of the "proceeds." On the face of it, the equity deal may be justified, although it does not hold a board and fulfill its obligation to disclose information to listed companies.　　But in fact, behind the deal, there is a hidden story between executives and big shareholders. 1.485 million lost 17 million.　　In 2007, the main shareholder of Tianmu Pharmaceutical Co., Ltd. (hereinafter referred to as the modern investment in the days of the pharmaceutical industry 13.2 million yuan loans, in order to pay Paul, modern investment from the Songshan real estate to borrow 12 million yuan also on the loan.　　And in order to make up for the "East wall"-Songshan real estate hole, the main shareholders of the Tianmu pharmaceutical industry control of senior executives without the approval of the board, the generals to create a 4.5% stake in the shares sold to Songshan Real estate.　　Obvious is an equity deal, but it is more like a pledge. Because, until the end of March 2009 to pay the deadline, the equity transfer has been delayed.　　It's time to publish the annual report. Helpless, Tianmu pharmaceutical industry in the preparation of the 2008 Annual report, simply will be 9.9 million yuan in the cost of other accounts receivable, as for the profit of 1.485 million yuan, can only be recorded as "due to a certain degree of uncertainty recovery, temporarily not confirm the transfer proceeds."　　Subsequently, although the Zhejiang Provincial Securities and Regulatory Bureau has found that the day eye pharmaceutical industry in the stock exchange, without the consent of the Board of Directors to carry out the transfer of shares of the act of negligence, but can only default on this transaction fait accompli, and finally just ordered the days of the drug industry "as soon as possible to recover accounts　　Although Tianmu has earned 1.485 million yuan on the transfer, it has also dropped to 5.5% from the initial 10% per cent of its holdings in the sector.　　In the face of the imminent gain of 370 million yuan, the profit of Tianmu pharmaceutical industry is naturally from the 37 million yuan to cut into 20 million yuan, a full profit of 17 million yuan. And the damage is just beginning. According to reporters from the company to learn from the exchange, the company as the Shanghai Xuhui Sasac under the background of the state-funded companies, has raised more than 800 million yuan, in its investment in many small and medium-sized enterprises, already have 8 companies ready to go public. Among them, the 8.5% per cent of the compass (430011) will also be intended to be listed from the Sanbanxi market on the motherboard board.